Evidence map›Paper›PMID 42401791›Full record

ArticleMolecular medicine (Cambridge, Mass.)2026

PD-L1 and PD-L2 regulate in cell-autonomous and N-glycosylation-dependent manners the pro-tumorigenic characteristics and functions of human cancer-associated fibroblasts.

Alaa Abu Raiya, Tsipi Meshel, Iris Kamer, Christina Lipin, Raneen Tarabe, Amit Kessel, Tamar Horvitz, Linor Rubinstein-Achiasaf, Dina Morein, Jair Bar and 1 more

Abstract read
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alaa Abu RaiyaThe Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
Tsipi MeshelThe Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
Iris KamerJusidman Cancer Center, Sheba Medical Center, Ramat Gan, Israel.
Christina LipinThe Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
Raneen TarabeDepartment of Clinical Microbiology and Immunology, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Amit KesselSchool of Neurobiology, Biochemistry and Biophysics, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
Tamar HorvitzThe Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
Linor Rubinstein-AchiasafThe Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
Dina MoreinThe Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
Jair BarJusidman Cancer Center, Sheba Medical Center, Ramat Gan, Israel.
Adit Ben-BaruchThe Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel. aditbb@tauex.tau.ac.il.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTumor progression is regulated by cancer-associated fibroblasts (CAFs), pro-inflammatory cytokines (e.g., TNFα, IL-1β, IFNγ) and acquired immunity (such as inhibitory immune checkpoints: PD-L1, PD-L2). Here, we determined the interactions between these elements by analyzing the impact of pro-inflammatory cytokines on the proportions of PD-L1 + PD-L2-expressing CAFs; the cell-autonomous regulation of pro-tumorigenic characteristics and functions of CAFs by PD-L1/PD-L2; and the control of PD-L1/PD-L2 activities in CAFs by their N-glycosylation.

methodsCAFs were obtained from breast and lung cancer patients (BC-CAFs, Lung-CAFs). PD-L1/PD-L2 surface and whole-cell expression were determined by flow cytometry and Western blot, respectively. CAFs were transduced to express WT-PD-L1, WT-PD-L2, WT-PD-L1 + WT-PD-L2, PD-L1/PD-L2 N-glycosylation mutants or vector controls, followed by determination of the pro-tumorigenic factors osteopontin (qRT-PCR) and CXCL8 (IL-8)/CCL2 (MCP-1)(ELISA). The effects of factors produced by CAFs expressing WT-PD-L1/WT-PD-L2/their N-glycosylation mutants on tumor cell migration were analyzed by wound-healing assays.

resultsTNFα + IL-1β potently increased the expression of CXCL8, whereas IFNγ stimulation up-regulated the proportions of BC-CAFs and Lung-CAFs expressing PD-L1 + PD-L2 at cell surface. Combined TNFα + IL-1β + IFNγ stimulation has prominently increased intracellular pools of N-glycosylated PD-L1 and PD-L2, in BC-CAFs and Lung-CAFs. WT-PD-L1 induced in cell-autonomous manners pro-tumorigenic characteristics and functions in BC-CAFs: elevated the expression of osteopontin, CXCL8 and CCL2 and induced the production of factors that promoted tumor cell migration. WT-PD-L2 also acted in a cell-autonomous manner in BC-CAFs, generally down-regulating these phenotypes and activities. When co-expressed in BC-CAFs, the cancer-supporting effects of WT-PD-L1 dominated the anti-tumorigenic impacts of WT-PD-L2. The cell-autonomous functions of PD-L1 and PD-L2 were regulated, in context- and function-dependent manners, by their N-glycosylation sites, primarily N35/N192 in PD-L1 and N37/N163 in PD-L2.

conclusionsChronic inflammation can up-regulate the proportions of PD-L1 + PD-L2 expressing CAFs. PD-L1 and PD-L2 act in cell-autonomous manners to control the pro-tumorigenic characteristics and functions of CAFs, with dominance of the tumor-promoting effects of PD-L1 over the tumor-inhibiting roles of PD-L2. The cell-intrinsic functions of PD-L1 and PD-L2 in CAFs depended on their N-glycosylation. These observations emphasize the need to consider the expression of PD-L1 and PD-L2 in stromal cells when designing treatments with immune checkpoint blockades in patients.

Indexed as

B7-H1 AntigenCancer-Associated FibroblastsProgrammed Cell Death 1 Ligand 2 ProteinCell Line, TumorCell MovementCytokinesFemaleGlycosylationHumansLung NeoplasmsB7-H1 AntigenCD274 protein, humanCytokinesPDCD1LG2 protein, humanProgrammed Cell Death 1 Ligand 2 ProteinCancer-associated fibroblastsInterferon γInterleukin 1βMigrationN-glycosylationPD-L1PD-L2Pro-inflammatory cytokinesTumor necrosis factor α

Identifiers

PMID42401791
PMCPMC13587499

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.